HCV is a bloodborne virus. Serological studies employing EIAs for detection of antibodies to recombinant antigens of HCV have established HCV as the cause of most bloodborne as well as community-acquired
non-A, non-B hepatitis. The presence of anti-HCV indicates that an individual may have been infected with HCV, may harbor infectious HCV, and/ or may be capable of transmitting HCV infection. Although the majority of infected individuals may be asymptomatic, HCV infection may develop into chronic hepatitis, cirrhosis, and/or increased risk of hepatocellular carcinoma. The implementation of blood donation screening for anti-HCV by EIAs has led to a marked decline in the risk of transfusiontransmitted hepatitis.
Manufacturer’s Reagent package insert Architect Anti-HCV, November 2014, Abbott GmbH &Co.KG, MAX-Planck-Ring 2, 65205 Wiesbaden, Germany